1-[(4-Isothiocyanatophenyl)methyl]-1,4,7,10-tetrazacyclododecane

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-[(4-Isothiocyanatophenyl)methyl]-1,4,7,10-tetrazacyclododecane
• 英文别名: 1-[(4-isothiocyanatophenyl)methyl]-1,4,7,10-tetrazacyclododecane
• 化学式: C₁₆H₂₅N₅S
• 分子量: 319.5
• InChiKey: HSCYYRRAZJLRPM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  83.8
• 氢给体数：
  3
• 氢受体数：
  6

文献信息

• RADIOPHARMACEUTICAL SOLUTIONS WITH ADVANTAGEOUS PROPERTIES
  申请人：Sciencons AS

  公开号：EP3261681A1

  公开（公告）日：2018-01-03
• COMBINATION IMMUNOTHERAPY AND CHEMOTHERAPY FOR THE TREATMENT OF A HEMATOLOGICAL MALIGNANCY
  申请人：Actinium Pharmaceuticals, Inc.

  公开号：EP3740235A1

  公开（公告）日：2020-11-25
• COMBINATION RADIOIMMUNOTHERAPY AND CD47 BLOCKADE IN THE TREATMENT OF CANCER
  申请人：ACTINIUM PHARMACEUTICALS, INC.

  公开号：US20220211886A1

  公开（公告）日：2022-07-07

  Provided are compositions and methods for treating cancers and precancerous proliferative disorders in a mammalian subject that involve the combination use of a radiotherapeutic agent, such as a radiolabeled CD33, DR5, 5T4, HER2, HER3, or TROP2 targeting agent, and a CD47 checkpoint inhibitor, such as a SIRPα-IgG Fc fusion protein or a monoclonal antibody against CD47 or SIRPα.
• [EN] RADIOPHARMACEUTICAL SOLUTIONS WITH ADVANTAGEOUS PROPERTIES<br/>[FR] SOLUTIONS RADIOPHARMACEUTIQUES PRÉSENTANT DES PROPRIÉTÉS AVANTAGEUSES
  申请人：SCIENCONS AS

  公开号：WO2016135200A1

  公开（公告）日：2016-09-01

  The present invention relates to radiopharmaceutical compositions comprising the mother nuclide 224Ra, its daughter nuclide 212Pb, and a complexing agent that complexes with the daughter nuclide. The use of targeted chelate scavengers for 224Ra daughter nuclide opens up the possibility for using 224Ra based solutions for medical treatments.
• [EN] COMBINATION IMMUNOTHERAPY AND CHEMOTHERAPY FOR THE TREATMENT OF A HEMATOLOGICAL MALIGNANCY<br/>[FR] IMMUNOTHÉRAPIE ET CHIMIOTHÉRAPIE COMBINÉES POUR LE TRAITEMENT D'UNE MALIGNITÉ HÉMATOLOGIQUE
  申请人：ACTINUM PHARMACEUTICALS INC

  公开号：WO2019136422A1

  公开（公告）日：2019-07-11

  Methods for treating a proliferative disease by administering a synergistic combination of an antibody against an epitope of CD33 (anti-CD33) and a combination of two or more individual chemotherapeutic agents is disclosed. The combination of chemotherapeutic agents may include cladribine, cytarabine, mitoxantrone, and filgrastim (CLAG-M), and the anti-CD33 may be a humanized monoclonal antibody against CD33 such as HuM195 conjugated with a radionuclide such as 131I or 225 Ac. The proliferative disease or disorder may be a hematological disease such as multiple myeloma, acute myeloid leukemia, and/or myelodysplastic syndrome. The method may be particularly useful for treatment of relapsed or refractory acute myeloid leukemia.